Podcast Episodes
Back to SearchComputational Drug Discovery With Gain Therapeutics' Matthias Alder
We love to hear from our listeners. Send us a message.
Gain Therapeutics' newly-appointed CEO Matthias Alder offers up a deep, yet abundantly clear e…
3 years ago
Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany
We love to hear from our listeners. Send us a message.
Join Matt Pillar for a conversation with Carine Boustany, PharmD and SVP, US Research Site Hea…
3 years ago
AI & Computational Biology With Recursion's Chris Gibson, Ph.D.
We love to hear from our listeners. Send us a message.
Recursion's unique, technology-aided approach to drug discovery has yielded one of the deepest…
3 years ago
Allan Shaw On Financing Biopharma Innovation
We love to hear from our listeners. Send us a message.
Friend and frequent guest Allan Shaw rejoins the Business of Biotech to reflect on his recent …
3 years, 1 month ago
Gene Therapy For Chronic Inflammation With Xalud's Howard Rutman, M.D.
We love to hear from our listeners. Send us a message.
While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is takin…
3 years, 1 month ago
The Antibody Engine With Abpro's Chan Brothers
We love to hear from our listeners. Send us a message.
In an industry that takes new business naming conventions to extremes, Abpro is a refreshingly…
3 years, 1 month ago
In-Vivo CAR T Update With Umoja Biopharma's David Fontana, Ph.D.
We love to hear from our listeners. Send us a message.
2023 is just around the corner, and it's shaping up to be a big year for Umoja Biopharma. The …
3 years, 1 month ago
RNA-Based Therapeutics With Nutcracker Therapeutics' Dr. Geoff Nosrati
We love to hear from our listeners. Send us a message.
Nutcracker Therapeutics is a preclinical biopharma company developing multimodal RNA-based th…
3 years, 1 month ago
Tick-Derived Therapeutic Molecules With Akari Therapeutics' Rachelle Jacques
We love to hear from our listeners. Send us a message.
Ticks are a scourge. They're vectors of multiple serious an debilitating diseases, and evoluti…
3 years, 2 months ago
Product vs. Platform With Surface's Vito Palombella, Ph.D. and Robert Ross, M.D.
We love to hear from our listeners. Send us a message.
Earlier this month, Surface Oncology shared that it will open a second stage of its monotherap…
3 years, 2 months ago